NEW YORK, May 4, 2020 /PRNewswire/ -- Halper Sadeh LLP, a
global investor rights law firm, is investigating whether the sale
of Stemline Therapeutics, Inc. (NASDAQ: STML) to Menarini Group is
fair to Stemline shareholders. On behalf of Stemline shareholders,
Halper Sadeh LLP may seek increased consideration for shareholders,
additional disclosures and information concerning the proposed
transaction, or other relief and benefits.
If you are a Stemline shareholder and would like to discuss your
legal rights and options, please visit Stemline Merger or
contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or
sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Under the terms of the agreement, Stemline shareholders will
receive $11.50 in cash and one
non-tradeable Contingent Value Right that will entitle each holder
to an additional $1.00 in cash per
share upon completion of the first sale of ELZONRIS in any EU5
country after European Commission approval.
The Stemline merger investigation concerns whether Stemline
and its board of directors violated the federal securities laws
and/or breached their fiduciary duties to shareholders by failing
to: (1) obtain the best possible consideration for Stemline
shareholders; (2) determine whether Menarini Group
is underpaying for Stemline; and (3) disclose all material
information necessary for Stemline shareholders to adequately
assess and value the merger consideration.
If you are a Stemline shareholder and would like to discuss your
legal rights and options, please visit
https://halpersadeh.com/actions/stemline-therapeutics-inc-stml-stock-merger-menarini-group/
or contact Daniel Sadeh or
Zachary Halper at (212) 763-0060 or
sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world
who have fallen victim to securities fraud and corporate
misconduct. Our attorneys have been instrumental in implementing
corporate reforms and recovering millions of dollars on behalf of
defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stemline-merger-investigation-halper-sadeh-llp-announces-investigation-into-whether-the-sale-of-stemline-therapeutics-inc-is-fair-to-shareholders-investors-are-encouraged-to-contact-the-firm-301051977.html
SOURCE Halper Sadeh LLP